Patents by Inventor Hirokazu Matsumoto
Hirokazu Matsumoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090239839Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.Type: ApplicationFiled: February 24, 2009Publication date: September 24, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Fumio ITOH, Shuji Hinuma, Naoyuki Kanzaki, Hiroshi Mabuchi, Hiromi Yoshida, Hirokazu Matsumoto, Takeshi Wakabayashi
-
Publication number: 20090227501Abstract: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing/treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing/treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc.Type: ApplicationFiled: June 24, 2008Publication date: September 10, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Koh Takagi, Masaaki Mori
-
Publication number: 20090197395Abstract: A method of manufacturing a device includes: a laser beam-machined groove forming step of irradiating a wafer with a laser beam from the back side of the wafer along planned dividing lines so as to form laser beam-machined grooves along the planned dividing lines; an etching step of etching a back-side surface of the wafer having been subjected to the laser beam-machined groove forming step, so as to remove denatured layers formed at processed surfaces of the laser beam-machined grooves; an adhesive film attaching step of attaching an adhesive film to the back-side surface of the wafer having been subjected to the etching step, and adhering the adhesive film side of the wafer to a surface of a dicing tape; and an adhesive film rupturing step of expanding the dicing tape so as to rupture the adhesive film along individual devices.Type: ApplicationFiled: January 15, 2009Publication date: August 6, 2009Applicant: DISCO CORPORATIONInventors: Masaru Nakamura, Hirokazu Matsumoto
-
Publication number: 20090191692Abstract: A method of processing a wafer having a plurality of devices which are composed of a laminate consisting of an insulating film and a functional film on the front surface of a substrate, along streets for sectioning the plurality of devices, the method comprising a first blocking groove forming step for forming a first blocking groove for dividing the laminate in a one-side portion in the width direction of a street of the wafer held on a chuck table by moving the chuck table in a first direction in the processing-feed direction while activating a first laser beam application means; and a second blocking groove and dividing groove forming step for forming a second blocking groove which divides the laminate in the other-side portion in the width direction of the street of the wafer which has undergone the first blocking groove forming step by moving the chuck table in a second direction in the processing-feed direction while activating the first laser beam application means and at the same time, forming a dividType: ApplicationFiled: December 19, 2008Publication date: July 30, 2009Inventors: Kentaro IIzuka, Hirokazu Matsumoto, Ryugo Oba
-
Publication number: 20090138757Abstract: There is provided a method executed in a cluster system comprising a first computer and at least one second computer that stores the data transmitted from the first computer. The method comprising the steps of: judging whether the failure-occurred processing is restarted by the first computer or the failure-occurred processing is switched over by the second computer based on the system information; receiving the stored data from the second computer and re-executing the processing in which the failure has occurred by the first computer, in the case of which it is judged that the processing in which the failure has occurred is restarted by the first computer; and executing, by the second computer, the processing in which the failure has occurred, in the case of which it is judged that the processing in which the failure has occurred is switched over by the at least one second computer.Type: ApplicationFiled: March 3, 2008Publication date: May 28, 2009Inventors: Hirokazu Matsumoto, Tsunehiko Baba, Shinji Hamada, Takashi Ichimura, Noriaki Takahashi
-
Patent number: 7342105Abstract: The antibody of the present invention, which specifically reacts with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc.Type: GrantFiled: February 26, 2004Date of Patent: March 11, 2008Assignee: Takeda Chemcial Industries, Ltd.Inventors: Hirokazu Matsumoto, Eri Hashimoto, Masaaki Mori, Chieko Kitada
-
Patent number: 7323541Abstract: The present invention aims at providing a novel polypeptide, a receptor, a DNA thereof, and the like. Specifically, the present invention provides a polypeptide having a binding ability to the protein represented by SEQ ID NO: 1 or SEQ ID NO: 3, or its amide, its ester or its salt, a polynucleotide encoding the polypeptide, an antisense polynucleotide or an antibody to the polypeptide, a screening of agent for prevention and/or treatment of cancer, obesity, etc., which comprises using the above, and the like. The polypeptide, receptor, polynucleotide, antisense polynucleotide, antibody and the like are useful for an agent of prevention and/or treatment of cancer, obesity and the like. Further, they are useful for a screening of an agent for prevention and/or treatment of cancer, obesity and the like.Type: GrantFiled: September 13, 2002Date of Patent: January 29, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaaki Mori, Kozo Hayashi, Hiroyuki Miya, Shuji Sato, Chieko Kitada, Hirokazu Matsumoto, Toshimi Nagi, Yukio Shimomura
-
Publication number: 20070129348Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.Type: ApplicationFiled: April 15, 2004Publication date: June 7, 2007Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Hiroshi Mabuchi, Hiromi Yoshida, Hirokazu Matsumoto, Takeshi Wakabayashi
-
Publication number: 20070117840Abstract: A compound represented by the formula (I): wherein ring A represents an aromatic ring; X represents a bond, oxygen, NR4 (R4 represents hydrogen, a hydrocarbon group, or a heterocyclic group), or alkylene; R1 represents a hydrocarbon group, or a heterocyclic group; R2 represents —COYR5 (Y represents a bond, alkylene, oxygen, sulfur, or NR6 (R6 represents hydrogen, a hydrocarbon group, or a heterocyclic group), and R5 represents a hydrocarbon group, or a heterocyclic group), a hydrocarbon group, or a heterocyclic group; and R3 represents a hydrocarbon group, a heterocyclic group, optionally substituted hydroxy, optionally substituted amino, or —S(O)nR7 (R7 represents a hydrocarbon group, or a heterocyclic group, and n is 0 to 2), a salt of the compound, or a prodrug or either is useful as an agent for modulating the function of an RFRP receptor.Type: ApplicationFiled: March 16, 2004Publication date: May 24, 2007Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Yoshihiro Banno, Hiromi Yoshida, Hirokazu Matsumoto
-
Publication number: 20070072865Abstract: The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.Type: ApplicationFiled: August 26, 2004Publication date: March 29, 2007Inventors: Kohji Fukatsu, Yutaka Nakayama, Naoki Tarui, Masaaki Mori, Hirokazu Matsumoto, Osamu Kurasawa, Hiroshi Banno
-
Publication number: 20070042947Abstract: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing/treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing/treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc.Type: ApplicationFiled: March 11, 2004Publication date: February 22, 2007Applicant: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Koh Takagi, Masaaki Mori
-
Patent number: 7173112Abstract: The present invention intends to provide a novel monoclonal antibody having a binding specificity to GALP or its derivative, which is useful in developing therapeutic agents, preventive agents or diagnostic agent for diseases associated with GALP or its derivative, and a method of quantifying GALP using the antibody. More specifically, the present invention provides an antibody specifically reacting with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or its derivative, and a method of quantifying GALP or its derivative.Type: GrantFiled: September 25, 2002Date of Patent: February 6, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
-
Publication number: 20070014799Abstract: The present invention provides a novel antibody useful in developing therapeutic, preventive and diagnostic agents for diseases associated with human ZAQL-2, a method of quantifying ZAQL-2 by using the antibody, etc. More particularly, the present invention provides an antibody reacting specifically with human ZAQL-2 or its derivatives, a method of quantifying ZAQL-2 by using the antibody, a pharmaceutical drug comprising the antibody, and so on.Type: ApplicationFiled: October 21, 2004Publication date: January 18, 2007Inventors: Hirokazu Matsumoto, Jiro Noguchi, Yasushi Masuda
-
Publication number: 20060287227Abstract: Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals.Type: ApplicationFiled: March 11, 2004Publication date: December 21, 2006Inventors: Tetsuya Ohtaki, Hisanori Matsui, Hirokazu Matsumoto, Chieko Kitada
-
Publication number: 20060275286Abstract: The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically reacting with a partial peptide at the N-terminus or C-terminus of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or its derivative, and a method of detecting/quantifying metastin or its derivative using the antibody as well as a diagnostic agent using the same.Type: ApplicationFiled: August 2, 2006Publication date: December 7, 2006Applicant: Takeda Chemical Industries, Ltd.Inventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
-
Patent number: 7130752Abstract: In a measuring-instrument remote-calibration system and measuring-instrument remote-calibration method, a measuring standard quantity is converted into a parameter adapted for communication, or based on measuring standard quantity, a parameter adapted for communication is generated and sent to a remote place. Alternatively, when the measuring standard quantity is not suitable for communication, it is converted into a form adapted for transportation and the converted measuring standard quantity is sent to a remote place. After the converted measuring standard quantity reaches the place, it is restored to the original measuring standard quantity, thus enabling calibration. The result of the calibration is certified.Type: GrantFiled: October 31, 2003Date of Patent: October 31, 2006Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Haruo Yoshida, Hirokazu Matsumoto, Yoshio Hino, Masaru Arai, Masataka Nakazawa
-
Publication number: 20060241051Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: December 26, 2003Publication date: October 26, 2006Inventors: Chieko Kitada, Taiji Asami, Naoki Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Publication number: 20060217536Abstract: The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.Type: ApplicationFiled: January 21, 2004Publication date: September 28, 2006Inventors: Hirokazu Matsumoto, Yasuko Horikoshi
-
Patent number: 7112662Abstract: The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically reacting with a partial peptide at the N-terminus or C-terminus of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or its derivative, and a method of detecting/quantifying metastin or its derivative using the antibody as well as a diagnostic agent using the same.Type: GrantFiled: September 18, 2002Date of Patent: September 26, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
-
Publication number: 20060177449Abstract: The antibody of the present invention, which is specifically reacting with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc.Type: ApplicationFiled: February 26, 2004Publication date: August 10, 2006Inventors: Hirokazu Matsumoto, Eri Hashimoto, Masaaki Mori, Chieko Kitada